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ABSTRACT 
 
Human epidermal growth factor receptors (HER) are targeted by a growing number of 
inhibitors which directly block the receptors on HER-expressing tumor cells or interfere with 
their signaling pathways. However, HER-expression is variable between tumors and 
resistance against these drugs is a well-known clinical problem necessitating further 
research to optimize therapeutic regimes for HER-positive patients. Currently, information 
about the potential biomarker status is routinely obtained ex vivo from biopsy specimens. 
HER-targeted imaging biomarkers on the other hand, could measure in vivo the receptor 
expression across the entire disease burden and help to monitor early responses to 
treatment. This review describes current status of HER-specific imaging agents with a 
particular focus on moving these molecular probes from early preclinical studies to clinical 
trials.    
 
  
EGF RECEPTORS AS VALID IMAGING TARGETS 
 
The human epidermal growth factor family (HER) of receptor tyrosine kinases has been the 
focus of intense translational research over the past three decades. The HER family includes 
four members:  EGFR (HER1, ErbB1), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4). 
These structurally related proteins coordinate a complex signaling network that plays a 
crucial role in the development and evolution of cancer (Fig.1). There are at least eleven 
different ligands (e.g. epidermal growth factor (EGF), transforming growth factor (TGFa), 
neuregulins (NRGs) that are known to bind to these receptors. Although all four receptors 
have the same essential domains, the functional activity of each domain varies. HER2 does 
not have a known ligand, but exists in the extended ‘active’ conformation state, constitutively 
available for dimerization with the other three members. In contrast, HER3 can bind to 
several ligands but lacks fully intrinsic tyrosine kinase activity as it is unable to bind 
adenosine triphosphate. EGFR and HER4 have active tyrosine kinase domains and known 
ligands (1). Ligand binding triggers intracellular signaling through a tightly controlled network 
of downstream signaling mechanisms, which drive and regulate many cellular processes. 
The two main signaling pathways, which are utilized by all HER receptors, are the 
Ras/MAPK (mitogen-activated protein kinase) that leads to cellular proliferation, 
differentiation, as well as migration, and the PI3K (phosphatidylinositol3-kinase)/Akt that 
primarily serves to promote cell proliferation and survival through progression of the cell 
cycle and inhibition of apoptosis (2). Changes in the regulation of receptor activity may 
cause uncontrolled cell growth and result in the initiation and maintenance of several solid 
tumors, including breast, gastric, ovarian, and non-small cell lung cancers. Cancer patients 
whose tumors have HER alterations (e.g. receptor overexpression, mutation or gene 
amplification) tend to have more aggressive tumor behavior. Furthermore, in the majority of 
cases receptor-positivity is associated with resistance to certain types of chemotherapy, 
hormone therapy and ionizing radiation, consequently leading to a shorter time to disease 
progression and worse patient survival (2).  
These findings have led to the development and widespread implementation of 
specific HER inhibitors, including antibodies targeting the extracellular domain and small 
molecules that prevent phosphorylation of the intracellular domain (tyrosine kinase inhibitors; 
TKI). Several of these targeted drugs have been approved for clinical use including a 
recombinant humanized version of an anti-HER2 monoclonal antibody (mAb), trastuzumab 
(Herceptin®), which has shown significant clinical efficacy in HER2-overexpressing 
metastatic breast cancers when combined with chemotherapy. The success of trastuzumab 
was followed by the introduction of other therapeutic antibodies and antibody-drug 
conjugates (ADC) targeting the HER2, e.g. pertuzumab (Perjeta®) and the ADC 
trastuzumab-emtansine (T-DM1, Kadcyla ®). Among the small molecular inhibitors, lapatinib 
(Tykerb ®) has shown activity in HER2-positive cancers that have relapsed following 
trastuzumab treatment. Gefinitib (Iressa®) and erlotinib (Tarceva®) are further examples of 
TK inhibitors, which act on the epidermal growth factor receptor. The chimeric anti-EGFR 
monoclonal antibody cetuximab (Erbitux®) is used for the treatment of metastatic colorectal 
cancer, metastatic non-small cell lung cancer and head and neck cancer. 
Even though these targeted therapies have improved the treatment outcome in the 
early stage of cancer, many tumors still manifest intrinsic resistance and even those that 
initially respond to the treatment develop resistance within a year.  
The receptor status thus represents a major factor in selecting patients for targeted 
therapies, therefore more precise assessment of the HER family expression levels and 
activation of downstream signaling pathways would prove beneficial in identifying new 
treatment paradigms.  
 Currently, HER-specific alterations (e.g. protein overexpression, receptor mutation, 
translocation, and epigenetics changes) can be analyzed by methods such as: 
immunohistochemistry (IHC), quantitative polymerase chain reaction, proteomics, next-
generation sequencing of the tumor tissues derived postoperatively or via biopsies. These 
techniques aid in our understanding how cancer cells adapt to the treatment and become 
resistant to it. However, these are invasive methods prone to sampling errors and most likely 
confounded by inter- and intratumor heterogeneity of receptor expression within analyzed 
biopsy specimens. Moreover, collecting sequential biopsies to monitor changes in receptor 
expression over time in response to treatment is not only practically difficult and ethically 
challenging, but also it will not reflect the presence of the resistant clones in multiple 
metastatic sites. Therefore, developing and validating non-invasive specific imaging 
biomarkers capable of confirming the presence of accessible targets early in the disease 
progression may help to resolve the dilemmas in which information about protein status is 
essential when considering a new treatment regimen and the biopsy is impractical. 
Positron emission tomography (PET) using radiolabeled mAbs, antibody fragments or 
engineered protein scaffolds (immuno-PET), has the potential to offer non-invasive criteria 
able to identify the presence and accessibility of the target, to measure more accurately 
tumor response in a timely fashion (e.g. immediately following treatment initiation), as well as 
to assist in patient stratification.  Furthermore, immuno-PET can provide information about 
the heterogeneity of both target expression and therapeutic response, which are increasingly 
recognized as key factors in therapeutic resistance, especially in patients with advanced 
disease where target expression may vary from site to site and biopsy of a single site may 
not represent the entire burden of a disease. The non-invasive nature of immuno-PET also 
allows for performing multiple imaging sessions to adequately assess treatment response by 
longitudinal studies.  
Although introduction of immuno-PET into routine clinical practice may add some complexity 
and increase costs of studies, with the appropriate use it has the potential to assess the 
efficacy of novel anti-cancer compounds during the early stages of development. It will lead 
to minimizing the investment wasted by taking ineffective treatments through further clinical 
testing. Noteworthy, in 2012 Pfizer announced that 43% of their Phase II trials failed due to a 
negative outcome at clinical proof-of-concept studies, where the candidate-drug mechanism 
of action was not adequately tested in an earlier phase of development (3). 
 
ROLE OF IMAGING HER RECEPTORS IN PATIENT STRATIFICATION AND 
MONITORING THERAPY RESPONSE 
 
With the increasing number of therapeutic antibody candidates targeting members of 
the HER family there is a need to better understand their biochemical/biological properties. 
Recently, several research groups have intensively worked on the development of imaging 
probes targeting these receptors, since the information about their expression helps to 
identify those patients who are likely to benefit from anti-HER targeted therapies. However, 
only a few studies have explored the relationship between imaging, genomics, and 
histopathology, therefore there is still a need for larger prospective studies to elucidate 
whether these methods can play a complementary role in assessing target expression and if 
their  combination may prove useful.  
A growing spectrum of radionuclides with longer half-life has recently become available for 
conjugation with mAbs. The most frequently used are 124I (t½ = 4.17 days), 64Cu (t½ = 12.7 h) 
and, 89Zr (t½ = 78.4 h). Depending on the radioisotope, different labeling methods are used. 
Iodine can be directly attached to mAb through the simple and widely available procedures, 
whereas radiometals are introduced indirectly by first conjugating the suitable chelator to the 
mAb and then non-covalently binding the metal ion. Among the radiometals 89Zr is the 
isotope of choice for mAbs that become internalized upon binding to its target since it 
becomes trapped (residualized) inside the cell and its physical half-life matches well the 
relatively slow pharmacokinetics of mAbs in solid tumors.   
Furthermore, it can be chelated by DFO under mild conditions which do not affect mAb 
structure. But slow clearance of intact mAbs requires a prolonged interval from injection to 
scan and one of the principal concerns regarding the use of 89Zr in the clinic is the 
substantial radiation dose received by patients compared to shorter-lived nuclides. Indeed, it 
has been reported for example that  89Zr-trastuzumab (37 MBq; 18 mSv) leads to 2.5-fold 
higher radiation exposure when compared to conventional 18F-FDG PET (37 MBq, ~7 mSv) 
(4). These considerations have prompted the development of alternative approaches such 
as engineered mAb fragments, diabodies, and affibodies that still have high specificity and 
affinity of the potential therapeutic mAb, but their molecular weight below 60 kDa allows for 
rapid renal clearance and elimination. The clearance time of these targeting agents also 
matches the favorable short half-life of 18F (t½ = 109.8 min) allowing for same day imaging. 
 Many preclinical small animal studies have been performed with 89Zr-labelled anti-HER 
radioligands to determine their tumor targeting characteristics. Knowledge obtained in these 
studies has made the translation of these agents into clinical trials possible. Typical 
examples of such practice comes from breast cancer studies where the development of 
HER2-targeted therapies was one of the most significant breakthroughs in the treatment of 
HER2-positive patients leading to a marked increase in therapeutic response. However, due 
to disease heterogeneity, the reported discordance between HER2 status in primary tumor 
and metastasis measured by IHC has been very high (13-30%) indicating the need for 
introducing immuno-PET imaging into clinical practice. Figure 2 shows a typical example of 
89Zr-labeled trastuzumab PET/CT in a patient with metastatic breast cancer.  
An interesting early example is a study presented by Dijkers et al. in HER2-positive breast 
cancer patients (4). The authors demonstrated high accumulation of 89Zr-trastuzumab in 
HER2-positive lesions in the liver, lung and bone. Additionally, unknown metastases were 
detected across a locally compromised blood-brain barrier. Also, 64Cu-DOTA-trastuzumab 
has shown promise in early clinical trials (5). In another study, Smith-Jones et al. have 
shown that 68Ga-labelled Fab fragments detect different levels of HER2 receptors in 
preclinical models (6) and this approach has already demonstrated its feasibility in an early 
clinical study (7). Besides, preclinical imaging using 89Zr-trastuzumab has also been used to 
monitor a decrease in HER2 expression in response to drugs targeting Hsp90, a chaperone 
protein that plays an important role in mediating HER2 expression. Interestingly, these 
studies have recently been translated to early-stage human trials, where 89Zr-trastuzumab 
imaging was used to measure changes in HER2 expression in response to the Hsp90 
inhibitor NVP-AUY922 (8). Furthermore, it is well known that for T-DM1 to be active, the 
presence of an intact HER2 receptor is of pivotal importance since the internalization of the 
cytotoxic moiety of the drug depends on the binding of trastuzumab to the external domain of 
HER2. Gebhart et al., at the 2014 ASCO meeting, presented data showing that the presence 
or absence of HER2, as indicated by the 89Zr-trastuzumab uptake and a response, as 
indicated by decrease in 18F-FDG uptake provided an essentially 100% accurate prediction 
of later clinical response to HER2-directed therapy with T-DM1 administration in metastatic 
HER2 positive breast cancer (NCT01565200 clinical trial) (9). This trial is a great example 
indicating that 89Zr-trastuzumab is an accurate non-invasive test capable of identifying non-
responding patients prior to TDM1 administration. Recently, several groups including ours 
have also tested the feasibility of using affibody molecules specifically targeting HER 
receptors (10). In 2010 the first clinical studies using 68Ga and 111In-labelled Affibody-based 
HER2 imaging agents were performed (DOTA[0]-Z [HER2:342-pep2, ABY-002, ABY-025). 
Both compounds showed specific tumor uptake and allowed for high contrast imaging of 
HER2-positive tissues (11,12). Combined, these results further strengthen the applicability 
and promising future of HER2 imaging as routine clinical practice. 
89Zr-labelled anti-EGFR mAb cetuximab has also been investigated but most studies to date 
have been carried out in animal models. Several groups have shown that receptor 
expression level alone is not sufficient to predict patient response to anti-EGFR therapies 
and that there is no correlation between tracer uptake and protein level evaluated by IHC 
(13). Other studies have demonstrated that the majority of tumors responding to EGFR 
kinase inhibitors harbor activating mutations in the EGFR kinase domain (14) suggesting 
that imaging of EGFR mutant expression could be more useful in selecting the right patient 
population for personalized treatment. On the other hand, Chang et al. have recently shown 
that the uptake of EGFR-targeted 89Zr-panitumumab correlated well with the EGFR 
expression (15), and van Dijk et al. have presented that 111In-cetuximab-F(ab’)2 can be used 
to monitor the effects of EGFR inhibition combined with irradiation in head and neck 
carcinoma models (16). Also, comprehensive reviews on PET imaging of EGFR expression 
and multimodality imaging the HER-kinase axis in cancer have been published elsewhere 
(17,18). Similarly to HER2- and EGFR-PET, the very recent preclinical and clinical data 
emphasizes the potential of HER3-imaging. This receptor is the only member of the family 
that lacks fully catalytic kinase activity and accordingly its activation following heregulin 
binding is inherently dependent on heterodimerization with other members of the EGFR 
family. Beyond that, unlike other HER receptors, HER3 has 14 tyrosines in the C-terminal 
tail; six of them are docking sites directly recruiting the p85 subunit of PI3 kinase. As a 
consequence, HER3 is a key node in the activation of the PI3K/AKT pathway, promoting 
tumor cell survival, proliferation, and metastasis (19). Recent studies have highlighted HER3 
as a fundamental signaling receptor involved in the establishment of malignancy with several 
groups demonstrating that HER3 overexpression correlates with advanced disease stage 
and decreased overall survival (20). In addition, emerging evidence from studies of EGFR- 
and HER2-driven cancers have shown that these cancers invariably become resistant to 
anti-HER therapies, indicating that HER3 mediates in their treatment failures (21). For 
example, it has been demonstrated that there is a strong association between sensitivity to 
TK inhibitors including gefitinib and erlotinib and HER3 inactivation (22,23). These 
observations suggest that up-regulation of HER3 receptors might be an indication of poor 
prognosis, where agents targeting HER3 could potentially provide a novel approach towards 
the treatment of such cancers.  
Since HER3 lacks enzymatic activity, efforts have been put towards the development of 
mAbs targeting the receptor ectodomain and inhibiting various mechanisms by which HER3 
can become activated, with some being alrady in phase I and II clinical trials (i.e. MM-121, 
U3-1287, and LJM716) (24,25). The preclinical findings that have been presented so far with 
these mAbs appear to be very promising. or example, the study of MM-121 combined with 
the anti-EGFR mAb cetuximab in a mouse model of lung cancer clearly showed that 
resistance to cetuximab is due to HER3 ctivation, and blocking HER3 signaling by adding 
MM-121 into treatment combination led to a greater and more durable response (26). 
Moreover, LJM716 has shown significant growth inhibitory effects in HER2-positive cells and 
xenograft models when combined with trastuzumab or cetuximab (27).  
However, the activity of HER3 selective drugs in humans has not been robustly 
demonstrated and the overall data may be viewed as modest. Recently, Patritumab (U3-
1287) was used in combination with erlotinib in NSCLC patients who had progressed after at 
least one course of chemotherapy. The authors reported that the efficacy of the combination 
was encouraging, but there was no clear correlation between tumor response and HER3 
expression in tumor tissues or serum soluble HER3 levels. The lack of correlation could be 
due to the type of tumor tissues that were used (an archived tissue from the initial diagnosis) 
or the relatively low number of patients enrolled in the study (28). Therefore, the absence of 
a suitable biomarker to evaluate HER3 status still remains the major hurdle in the 
development of HER3-targeted therapies and effective patient selection. Consideration has 
been given to markers established for overexpression of partner kinases, such as HER2 or 
markers for the expression level of ligands that activate HER3 (e.g. NRG-1). For example, 
Schoeberl et al. have shown that the level of NRG-1 can be a better biomarker than receptor 
expression for the selection of patients that may benefit from MM-121 treatment (26). But 
even though NRG-1 is the most potent inducer of HER3 phosphorylation, using it as an 
effective biomarker might be quite limiting due to the existence of multiple routes of HER3 
activation, such as mutation, ligand-independent dimerization and potential contribution in 
receptor activation from other HER family ligands.  
In light of these findings, there is clearly a need for the development of imaging biomarkers 
that could guide the clinical use of innovative anti-HER3 targeted therapies. So far, to assess 
the HER3 tumor status, 89Zr radiolabelled mAb (GSK2849330) is being evaluated in patients 
with advanced solid tumors (clinical trial; NCT12345174).  
In addition, a novel 111In-labelled bispecific agent consisting of a trastuzumab Fab fragment 
targeting HER2 and NRG-1 targeting HER3 has been shown using small-animal SPECT/CT 
to specifically accumulate in tumor xenografts where HER2 is co-expressed with HER3 (29).   
Recently, we have developed a 89Zr-labelled AffibodyHER3:8698 recognizing the HER3 antigen 
(Fig.3). High tracer accumulation was found in human breast cancer MCF-7 and BT-474 
(HER3+++) xenografts but not in MDA-MB-231 tumors (HER3+) confirming the binding 
specificity of the probe. Similar high contrast images between targeted and non-targeted 
tissues were obtained for 89Zr-RG7116, an anti-HER3 antibody (30), but it required 144 
hours for the mAb to be cleared, whereas the 89Zr-AffibodyHER3:8698 provided images within 
the 1-3 h post injection. Furthermore, when mice bearing MCF-7 tumors were treated with 
AUY922, an Hsp90 inhibitor that is known to induce proteasome mediated degradation of 
phosporylated HER2 and HER3, there was a significantly higher tumor uptake of 89Zr-
AffibodyHER3:8698 in mice receiving the drug than in the control animals. This unexpected 
enhancement in HER3 expression following the treatment has been found to correlate with 
the recovery of HER3 and subsequent upregulation of the insulin-like growth factor 1 (IGF-1) 
receptor  and activation of the PI3K/AKT pathway (data on file). This data underlines the 
potential of a HER3 imaging agent as a tool for not only patient stratification for HER3 
targeted therapies but, more importantly, also for monitoring receptor level during 
therapeutic interventions. 
 
CONSIDERATIONS AND FUTURE PERSPECTIVES 
 
The observations that HERs are key players in the establishment of malignancy have 
led to a number of mAbs and T inhibitors, blocking EGFR and HER2, resulting in clinically 
meaningful anti-cancer activity. Continuously growing evidence points to HER3 upregulation 
as an important factor in resistance to HER-targeted therapies. The number of anti-HER3 
antibodies currently under development and tested in the clinical trials further underscores 
the importance of this target. Experimental and clinical evidence suggest that the dynamics 
of HER3 force to combine agents that directly block HER3 with compounds that interfere 
with receptor dimer signaling. Specific imaging agents could provide unique information as 
cancer biomarkers, including quantification of receptor heterogeneity and early detection of 
changes in target expression in response to therapy in parallel to high throughput 
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Figure 2. Whole body PET (A) and transaxial PET/CT (B-D) 96 hours after intravenous 
injection of 37 MBq 89Zr-trastuzumab in a patient with HER2-postive breast cancer 
metastatic to the liver (blue arrow), lymph nodes (red *) and bone (green *).  








Figure 3. A. 89Zr-AffibodyHER3:8698 uptake 3 h post injection in mouse bearing MCF-7 tumor. B. 
Ex vivo HER3 immunohistochemistry staining of MCF-7 tumor showing distribution of HER3 
receptors at different tumor regions. C. Confocal microscopy image of HER3-positive MCF-7 
cells exposed to AffibodyHER3:8698-DyLight-633. D. Diagram illustrating potential routes of 
inhibiting HER2/HER3 pathway activation and imaging the receptor status.   
 
 
 
 
 
 
 
